Colin Andrew Underwood

Colin Andrew Underwood
Experience 5.0 star rating
Industry Recognition 2.0 star rating
Professional Conduct 5.0 star rating

What is the Avvo Rating?

Client Reviews

Not yet reviewed
No professional misconduct found.

Contributor level 1

View contributions

Overview

Practice Areas

Chart?chs=124x124&cht=p&chp=4
  • 50% Antitrust / Trade Law
    23 years, 10 cases
  • 30% Litigation
    23 years, 11 cases
  • 15% Intellectual Property
    23 years, 6 cases
  • 5% Arbitration
    15 years, 3 cases

Contact Information

  • Cadwalader, Wickersham & Taft LLP
    One World Financial Center
    New York, NY 10281
    Office: 212-504-6650
    View map | Edit this address

References

Client Reviews

How would you rate this lawyer?

If you're a current or former client, share your thoughts (anonymously, if you prefer). Would you recommend this lawyer to other clients?

Review this lawyer

Peer Endorsements

Endorse a fellow lawyer, get more visits to your profile

In addition to providing a simple way to express your gratitude to fellow lawyers, any time you add an endorsement to a peer's profile, a link to your profile will appear on it.

Endorse this lawyer

Résumé

 

License

23 years since Colin Andrew Underwood was first licensed to practice law.

State License status Year acquired Last updated by Avvo
New York Currently registered 1990 05/21/2011

We have not found any instances of professional misconduct for this lawyer.

Work Experience

Position Duration
Partner at Cadwalader, Wickersham & Taft LLP 2010–present
Partner at Proskauer Rose LLP 2003–2010
See all 3 job entries

Education

School Major Degree Graduated
Yale Law School J.D. 1990
University of Michigan Computer Science M.Sc. 1985
See all 3 degrees

Associations

Position Association Name Duration
Executive Committee New York State Bar Association, Antitrust Section 2008–present
New York State Bar Association 2000–present
See all 5 association entries

Portfolio

Publications

Article Publication Date
Do Recent Circuit Decisions Threaten the Hatch-Waxman Balance? Pharmaceutical Law & Industry Report 2002